NEW YORK (TheStreet) -- BioCryst Pharmaceuticals(BCRX) - Get Report shares are up 2.8% to $8.81 in early market trading on Tuesday after the company announced that it won a U.S. government contract to continue to develop its treatment for Ebola and other viruses.
The contract with the U.S. Department of Health and Human Services provides for a base contract of $12.1 million for continued development of its RNA pathogens treatment BCX4430, with an additional $22.9 million being set aside for additional development.
Ebola treatments like the one BioCryst is developing sent biotech companies' stocks soaring last year during the Ebola outbreak in West Africa that killed 10,000 people and led to a handful of cases in the U.S.
Other companies also currently working on Ebola treatments include GlaxoSmithKline (GSK) - Get Report, Sarepta Pharmaceuticals Inc(SRPT) - Get Report, Novavax(NVAX) - Get Report, Merck(MRK) - Get Report and Johnson & Johnson(JNJ) - Get Report, according to Reuters.
TheStreet Ratings team rates BIOCRYST PHARMACEUTICALS INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:
"We rate BIOCRYST PHARMACEUTICALS INC (BCRX) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- You can view the full analysis from the report here: BCRX Ratings Report